Navigation Links
Coapt Systems New CEO, Laureen DeBuono, to Fuel Company's Growth and Product Innovation
Date:6/13/2008

Experienced Medical Device Executive and Former CFO of Thermage Inc. To Drive Coapt's Growth In New Markets, Including Non-Invasive Aesthetics

PALO ALTO, Calif., June 13 /PRNewswire/ -- Coapt Systems, Inc., developer of bioabsorbable implants for the fixation of soft tissue in the plastic, reconstructive and sports medicine markets, announced today the appointment of Laureen DeBuono as its President and CEO. She will also serve as a member of the company's Board of Directors. DeBuono has more than 25 years of management experience in the medical device and technology markets. She was most recently CFO of Thermage, Inc., one of the leading medical device companies for aesthetic applications, where she was instrumental in building its growth platform and taking the company public in November 2006. At Coapt Systems, DeBuono will focus on growing core product revenue, building the technology platform, and expanding into new markets, including non-invasive aesthetics.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080613/AQF014)

"I am thrilled to join Coapt Systems as its President and CEO and to help the company achieve even greater success by taking advantage of new market opportunities," said DeBuono. "Coapt has established itself as a market leader and innovator, and the company has steadily increased its product offerings and customer base. Coapt is now poised to expand its innovative product line and to move into new markets, particularly non-invasive aesthetics."

The company has introduced seven products into the market since 2002, and over 65,000 patients worldwide have received ENDOTINE(TM) implants in facial rejuvenation procedures. The Company's products are sold in over 41 countries.

Coapt Systems, founded in 2000 by a practicing plastic surgeon, designs, develops, manufactures, and markets bio absorbable implants that provide surgeons with breakthrough soft tissue fixation technology. Coapt's revolutionary platform technology for soft tissue fixation enables surgeons to reduce operating time, facilitate minimally invasive procedures, minimize procedural complexity, and achieve improved surgical outcomes. Coapt's patented ENDOTINE family of products are used for plastic surgery procedures that require accurate soft tissue fixation either to opposing soft tissue or to bone. The ENDOTINE product line is becoming the standard of care in aesthetic facial procedures.

"Coapt Systems has all the necessary elements, including strong management and an innovative product line, to continue its strong pace of growth and expansion," said Brent Ahrens, general partner at Canaan Partners. "Coapt is a great example of the type of innovative, high-growth company meeting unmet medical needs we invest in at Canaan. Laureen is a great addition to the team with her extensive management experience and recent success in the growing field of non-invasive aesthetics. Under her leadership, Coapt is poised to achieve even greater success moving forward."

Prior to joining Thermage in 2003, DeBuono was a consulting EVP and CFO to several public and private technology and medical device companies. DeBuono was also EVP, COO and CFO of More.com, an Internet health products commerce company, and she was EVP, COO and CFO of Resound Corporation, a public, hearing products and communications company that was acquired by GN Great Nordic in 1999. She also served as EVP, General Counsel to Nellcor Puritan Bennett Inc., a $900M public respiratory products company, from 1992-1998, and negotiated the sale of the company to Mallinkcrodt, Inc. in 1998. She was a member of the Board of Directors of Invivo, Inc., a public patient safety monitoring company, from 1998-2004, and of VISX, Inc., a public vision correction company, from 2003-2005, both of which were acquired. DeBuono received her J.D. from New York University Law School, an M.A. from Stanford University and a B.A. from Duke University.

About Coapt Systems

Coapt's product lineup includes the ENDOTINE Forehead, Midface ST, Midface B, TransBleph, Triple, Ribbon and SurgiWire devices, all of which are FDA approved. The company is also developing products for hand tendon repair. Located in Palo Alto, California, Coapt Systems Inc. is a privately held company with 47 employees.

For further information, visit http://www.coaptsystems.com.


'/>"/>
SOURCE Coapt Systems Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
2. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
3. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. NxStage Medical Provides Update on Medisystems Acquisition
6. ICx Awarded $1.5 M Contract by Department of Homeland Security for Development of Next Generation Bio Aerosol Systems
7. Imaging Diagnostic Systems New Laser Breast Imaging Scanner Introduced in Malaysia
8. Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 2007
9. Biomaxx Systems Inc. Selected as Technical Consultant By Southern Cross Agricultural Developments
10. Sigma-Aldrich and Ingenuity Systems Announce Partnership to Create E-Commerce Search Solution Based on Biological Knowledge
11. Ingenuity Systems Joins Biomarkers Consortium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Seattle, WA (PRWEB) , ... June 23, 2016 ... ... technology, announces the release of its second eBook, “Clinical Trials Patient Recruitment and ... patient recruitment and retention in this eBook by providing practical tips, tools, and ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
Breaking Biology Technology:
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
Breaking Biology News(10 mins):